This company listing is no longer active
ALDEI Stock Overview
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Deinove SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.026 |
| 52 Week High | €0.31 |
| 52 Week Low | €0.0062 |
| Beta | 0.78 |
| 1 Month Change | 0% |
| 3 Month Change | 10.42% |
| 1 Year Change | -91.12% |
| 3 Year Change | -96.30% |
| 5 Year Change | -99.29% |
| Change since IPO | -99.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALDEI | FR Chemicals | FR Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | -0.03% |
| 1Y | -91.1% | 13.6% | 1.8% |
Return vs Industry: ALDEI underperformed the French Chemicals industry which returned 4% over the past year.
Return vs Market: ALDEI underperformed the French Market which returned 11.4% over the past year.
Price Volatility
| ALDEI volatility | |
|---|---|
| ALDEI Average Weekly Movement | n/a |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.7% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALDEI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ALDEI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 44 | Alexis Rideau | www.deinove.com |
DEINOVE SA, a biotechnology company, discovers, develops, and produces compounds from microbials for the health, nutrition, and cosmetics industries worldwide. The company’s pipeline includes DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers Dual-Acting Small Molecule Antibiotics, a class of dual activity antibiotics that develops a new class of 2-in-1 molecules whose structure results from the combination of two active antibiotic moieties.
Deinove SA Fundamentals Summary
| ALDEI fundamental statistics | |
|---|---|
| Market cap | €843.07k |
| Earnings (TTM) | -€7.37m |
| Revenue (TTM) | €241.00k |
3.5x
P/S Ratio-0.1x
P/E RatioIs ALDEI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALDEI income statement (TTM) | |
|---|---|
| Revenue | €241.00k |
| Cost of Revenue | €3.91m |
| Gross Profit | -€3.67m |
| Other Expenses | €3.71m |
| Earnings | -€7.37m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | -1,521.58% |
| Net Profit Margin | -3,058.92% |
| Debt/Equity Ratio | -127.0% |
How did ALDEI perform over the long term?
See historical performance and comparison